Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Taprenepag isopropyl is a highly selective agonist of the EP2 receptor.
In vivo | Intraocular pressure (IOP) typically stays within normal limits in the left eye treated with a vehicle solution, while the right eye, dosed with Taprenepag isopropyl, shows a reduction in IOP across all dosage groups. Notably, in the high-dose group, IOP decreases to levels below measurable thresholds (<4mm Hg) on Days 22 and 29. Administration of Taprenepag isopropyl, regardless of the dose, does not result in clinical signs, body weight changes, or ocular findings in the animals receiving the lowest dose (0.75 mg/day) [1]. |
別名 | PF-04217329 |
分子量 | 520.6 |
分子式 | C27H28N4O5S |
CAS No. | 1005549-94-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Taprenepag isopropyl 1005549-94-9 GPCR/G Protein Immunology/Inflammation Prostaglandin Receptor PF04217329 PF-04217329 PF 04217329 Inhibitor inhibitor inhibit